Heparin-binding epidermal growth factor-like growth factor regulates fibroblast growth factor-2 expression in aortic smooth muscle cells

Circulation Research

Volumn 79, Issue 2, 1996, Pages 263-270

  Peifley, Kimberly A ^a   Alberts, Gregory F ^a   Hsu, Debbie K W ^a   Feng, Sheau Line Y ^a   Winkles, Jeffrey A ^a,b  

^a HOLLAND LABORATORY   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

dexamethasone; fibroblast growth factor; heparin; heparin binding epidermal growth factor like growth factor; smooth muscle cell

Indexed keywords

CYCLOHEXIMIDE; DACTINOMYCIN; DEXAMETHASONE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR LIKE FACTOR; MESSENGER RNA; RECOMBINANT EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA MEDIA; ARTICLE; BLOOD VESSEL INJURY; CELL GROWTH; CONTROLLED STUDY; FIBROBLAST; GROWTH REGULATION; HUMAN; HUMAN CELL; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; REGULATORY MECHANISM;

EID: 0030038580     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.79.2.263     Document Type: Article

References (79)

1. Besner G, Higashiyama S, Klagsbrun M. Isolation and characterization of a macrophage-derived heparin-binding growth factor. Cell Regul. 1990;1:811-819.
2. Higashiyama S, Abraham JA, Miller J, Fiddes JC, Klagsbrun M. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science. 1991;251:936-939.
3. Higashiyama S, Lau K, Besner GE, Abraham JA, Klagsbrun M. Structure of heparin-binding EGF-like growth factor: multiple forms, primary structure, and glycosylation of the mature protein. J Biol Chem. 1992;267:6205-6212.
4. Ono M, Raab G, Lau K, Abraham JA, Klagsbrun M. Purification and characterization of transmembrane forms of heparin-binding EGF-like growth factor. J Biol Chem. 1994;269:31315-31321.
5. Naglich JG, Metherall JE, Russell DW, Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell. 1992;69:1051-1061.
6. Mitamura T, Higashiyama S, Taniguchi N, Klagsbrun M, Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem. 1995;270:1015-1019.
7. Higashiyama S, Iwamoto R, Goishi K, Raab G, Taniguchi N, Klagsbrun M, Mekada E. The membrane protein CD9/DRAP 27 potentiates the juxtacrine growth factor activity of the membrane-anchored heparin-binding EGF-like growth factor. J Cell Biol. 1995;128:929-938.
8. Besner GE, Whelton D, Crissman-Combs MA, Steffen CL, Kim GY, Brigstock DR. Interaction of heparin-binding EGF-like growth factor (HB-EGF) with the epidermal growth factor receptor: modulation by heparin, heparinase, or synthetic heparin-binding HB-EGF fragments. Growth Factors. 1992;7:289-296.
9. Thompson SA, Higashiyama S, Wood K, Pollitt NS, Damm D. McEnroe G, Garrick B, Ashton N, Lau K, Hancock N, Klagsbrun M, Abraham JA. Characterization of sequences within heparin-binding EGF-like growth factor that mediate interaction with heparin. J Biol Chem. 1994;269:2541-2549.
10. Tan M, Tsai J, Lee Y, Chen H, Shin S, Lai Y, Perrella MA, Bianchi C, Higashiyama S, Endege W, Lee M, Tsai J. Induction of heparin-binding epidermal growth factor-like growth factor mRNA by protein kinase C activators. Kidney Int. 1994;46:690-695.
11. Hashimoto K, Higashiyama S, Asada H, Hashimura E, Kobayashi T, Sudo K, Nakagawa T, Damm D, Yoshikawa K, Taniguchi N. Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994;269:20060-20066.
12. Aviezer D, Yayon A. Heparin-dependent binding and autophosphorylation of epidermal growth factor (EGF) receptor by heparin-binding EGF-like growth factor but not by EGF. Proc Natl Acad Sci U S A. 1994;91:12173-12177.
13. Fukuda K, Inui Y, Kawata S, Higashiyama S, Matsuda Y, Maeda Y, Igura T, Yoshida S, Taniguchi N, Matsuzawa Y. Increased mitogenic response to heparin-binding epidermal growth factor-like growth factor in vascular smooth muscle cells of diabetic rats. Arterioscler Thromb Vasc Biol. 1995;15:1680-1687.
14. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993;122:933-940.
15. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
16. Nikkari ST, Clowes AW. Restenosis after vascular reconstruction. Ann Med. 1994;26:95-100.
17. Schwartz SM, deBlois D, O'Brien ERM. The intima: soil for athero-sclerosis and restenosis. Circ Res. 1995;77:445-465.
18. Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP, Quertermous T, Lee ME. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like growth factor gene in vascular endothelial cells. J Biol Chem. 1992;267:9467-9469.
19. Morita T, Yoshizumi M, Kurihara H, Maemura K, Nagai R, Yazaki Y. Shear stress increases heparin-binding epidermal growth factor-like growth factor mRNA levels in human vascular endothelial cells. Biochem Biophys Res Commun. 1993;197:256-262.
20. Temizer DH, Yoshizumi M, Perrella MA, Susanni EE, Quertermous T, Lee ME. Induction of heparin-binding epidermal growth factor-like growth factor messenger RNA by phorbol ester and angiotensin II in rat aortic smooth muscle cells. J Biol Chem. 1992;267:24892-24896.
21. Nakano T, Raines EW, Abraham JA, Wenzel FG, IV, Higashiyama S, Klagsbrun M, Ross R. Glucocorticoid inhibits thrombin-induced expression of platelet-derived growth factor A-chain and heparin-binding epidermal growth factor-like growth factor in human aortic smooth muscle cells. J Biol Chem. 1993;268:22941-22947.
22. Dluz SM, Higashiyama S, Damm D, Abraham JA, Klagsbrun M. Heparin-binding epidermal growth factor-like growth factor expression in cultured fetal human vascular smooth muscle cells. J Biol Chem. 1993;268:18330-18334.
23. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor synthesis by smooth muscle cells. Horm Res. 1994;42:9-13.
24. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lyso-phosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci U S A. 1994;91:1069-1073.
25. Pan Z, Kravchenko VV, Ye RD. Platelet-activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes. J Biol Chem. 1995;270:7787-7790.
26. 8+ T cells. Proc Natl Acad Sci U S A. 1994;91:2890-2894.
27. Peoples GE, Blotnick S, Takahashi K, Freeman MR, Klagsbrun M, Eberlein TJ. T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. Proc Natl Acad Sci U S A. 1995;92:6547-6551.
28. Miyagawa J, Higashiyama S, Kawata S, Inui Y, Tamura S, Yamamoto K, Nishida M, Nakamura T, Yamashita S, Matsuzawa Y, Taniguchi N. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest. 1995;95:404-411.
29. Pastore CJ, Isner JM, Bacha PA, Kearney M, Pickering JG. Epidermal growth factor receptor-targeted cytotoxin inhibits neointimal hyperplasia in vivo: results of local versus systemic administration. Circ Res. 1995;77:519-529.
30. Burgess WH, Winkles JA. The fibroblast growth factor family: multifunctional regulators of cell proliferation. In: Pusztai L, Lewis CE, Yap E, eds. Cell Proliferation in Cancer: Regulatory Mechanisms of Neoplastic Cell Growth. Oxford, England: Oxford University Press; 1996:154-217.
31. Fernig DG, Gallagher JT. Fibroblast growth factors and their receptors: an information network controlling tissue growth, morphogenesis and repair. Prog Growth Factor Res. 1994;5:353-377.
32. Cuevas P, Gonzalez AM, Carceller F, Baird A. Vascular response to basic fibroblast growth factor when infused onto the normal adventitia or into the injured media of the rat carotid artery, Circ Res. 1991;69:360-369.
33. Edelman ER, Nugent MA, Smith LT, Karnovsky MJ. Basic fibroblast growth factor enhances the coupling of intimal hyperplasia and proliferation of vasa vasorum in injured rat arteries. J Clin Invest. 1992;89:465-473.
34. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931-10934.
35. Parish MA, Grossi EA, Baumann FG, Asai T, Rifkin DB, Dolvin SB, Galloway AC. Effects of a single administration of fibroblast growth factor on vascular wall reaction to injury. Ann Thorac Surg. 1995; 59:948-954.
36. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106-113.
37. D'Amore PA, Smith SR, Growth factor effects on cells of the vascular wall: a survey. Growth Factors. 1993;8:61-75.
38. Hughes SE, Crossman D, Hall PA. Expression of basic and acidic fibroblast growth factors and their receptor in normal and atherosclerotic human arteries. Cardiovasc Res. 1993;27:1214-1219.
39. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF, Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and non-atherosclerotic arteries: association of acidic FGF with plaque microvessels and macrophages. J Clin Invest. 1993;92:2408-2418.
40. Flugelman MY, Virmani R, Correa R, Yu Z, Farb A, Leon MB, Elami A, Fu Y, Casscells W, Epstein SE. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. Circulation. 1993;88:2493-2500.
41. Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1991;88:3739-3743.
42. Nguyen HC, Steinberg BM, LeBoutillier M III, Baumann FG, Rifkin DB, Grossi EA, Galloway AC. Suppression of neointimal lesions after vascular injury: a role for polyclonal anti-basic fibroblast growth factor antibody. Surgery. 1994;116:456-462.
43. Jaye M, Lyall RM, Mudd R, Schlessinger J, Sarver N. Expression of acidic fibroblast growth factor cDNA confers growth advantage and tumorigenesis to Swiss 3T3 cells. EMBO J. 1988;7:963-969.
44. Bunnag P, Waddell KS, Varban ML, Chiu IM. Transformed phenotype conferred to NIH/3T3 cells by ectopic expression of heparin-binding growth factor-1/acidic fibroblast growth factor. In Vitro Cell Dev Biol. 1991;27:89-96.
45. Bikfalvi A, Klein S, Pintucci G, Quarto N, Mignatti P, Rifkin DB. Differential modulation of cell phenotype by different molecular weight forms of basic fibroblast growth factor: possible intracellular signaling by the high molecular weight forms. J Cell Biol. 1995;129:233-243.
46. Coltrini D, Gualandris A, Nelli EE, Parolini S, Molinari-Tosatti MP, Quarto N, Ziche M, Giavazzi R, Presta M. Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. Cancer Res. 1995;55:4729-4738.
47. 2 stimulates vascular smooth muscle hypertrophy by up-regulating the synthesis and release of endogenous basic fibroblast growth factor. J Biol Chem. 1993;268:17397-17403.
48. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest. 1993;91:2268-2274.
49. Koibuchi Y, Lee WS, Gibbons GH, Pratt RE. Role of transforming growth factor-β1 in the cellular growth response to angiotensin II. Hypertension. 1993;21:1046-1050.
50. Ali S, Becker MW, Davis MG, Dorn GW II. Dissociation of vaso-constrictor-stimulated basic fibroblast growth factor expression from hypertrophic growth in cultured vascular smooth muscle cells: relevant roles of protein kinase C. Circ Res. 1994;75:836-843.
51. Gay CG, Winkles JA. Interleukin 1 regulates heparin-binding growth factor 2 gene expression in vascular smooth muscle cells. Proc Natl Acad Sci U S A. 1991;88:296-300.
52. Winkles JA, Gay CG. Serum, phorbol ester, and polypeptide mitogens increase class 1 and 2 heparin-binding (acidic and basic fibroblast) growth factor gene expression in human vascular smooth muscle cells. Cell Growth Differ. 1991;2:531-540.
53. Sato Y, Hamanaka R, Ono J, Kuwano M, Rifkin DB, Takaki R. The stimulatory effect of PDGF on vascular smooth muscle cell migration is mediated by the induction of endogenous basic FGF. Biochem Biophys Res Commun. 1991;174:1260-1266.
54. Weiss RH, Maduri M. The mitogenic effect of thrombin in vascular smooth muscle cells is largely due to basic fibroblast growth factor. J Biol Chem. 1993;268:5724-5727.
55. Alberts GF, Hsu DKW, Peifley KA, Winkles JA. Differential regulation of acidic and basic fibroblast growth factor gene expression in fibroblast growth factor-treated rat aortic smooth muscle cells. Circ Res. 1994;75:261-267.
56. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994;90:649-652.
57. Gay CG, Winkles JA. The half-lives of platelet-derived growth factor A- and B-chain mRNAs are similar in endothelial cells and unaffected by heparin-binding growth factor-1 or cycloheximide. J Cell Physiol. 1991;147:121-127.
58. Tomita M, Hirata Y, Uchihashi M, Fujita T. Characterization of epidermal growth factor receptors in cultured vascular smooth muscle cells of rat aorta. Endocrinol Jpn. 1986;33:177-184.
59. Nanney LB, Stoscheck CM, King LE. Characterization of binding and receptors for epidermal growth factor in smooth muscle. Cell Tissue Res. 1988;254:125-132.
60. Scott-Burden T, Resink TJ, Baur U, Burgin M, Buhler FR. Epidermal growth factor responsiveness in smooth muscle cells from hypertensive and normotensive rats. Hypertension. 1989;13:295-304.
61. Epstein SE, Siegall CB, Biro S, Fu Y, Fitzgerald D, Pastan I. Cytotoxic effects of a recombinant chimeric toxin on rapidly proliferating vascular smooth muscle cells. Circulation. 1991;84:778-787.
62. Berk BC, Brock TA, Webb RC, Taubman MB, Atkinson WJ, Gimbrone MA Jr, Alexander RW. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin Invest. 1985;75:1083-1086.
63. MacDonald RG, Panush RS, Pepine CJ. Rationale for use of glucocorticoids in modification of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 1987;60:56B-60B.
64. Longenecker JP, Kilty LA, Johnson LK. Glucocorticoid inhibition of vascular smooth muscle cell proliferation: influence of homologous extracellular matrix and serum mitogens. J Cell Biol. 1984;98:534-540.
65. Voisard R, Seitzer U, Baur R, Dartsch PC, Osterhues H, Hoher M, Hombach V. Corticosteroid agents inhibit proliferation of smooth muscle cells from human atherosclerotic arteries in vitro. Int J Cardiol. 1994;43:257-267.
66. Chervu A, Moore WS, Quinones-Baldrich WJ, Henderson T. Efficacy of corticosteroids in suppression of intimal hyperplasia. J Vasc Surg. 1989;10:129-134.
67. Colburn MD, Moore WS, Gelabert HA, Quinones-Baldrich WJ. Dose responsive suppression of myointimal hyperplasia by dexamethasone. J Vasc Surg. 1992;15:510-518.
68. Villa AE, Guzman LA, Chen W, Golomb G, Levy RJ, Topol EJ. Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty. J Clin Invest. 1994;93:1243-1249.
69. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M, Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 1984;223:1296-1299.
70. Mignatti P, Morimoto T, Rifkin DB. Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum-Golgi complex. J Cell Physiol. 1992;151:81-93.
71. Florkiewicz RZ, Majack RA, Buechler RD, Florkiewicz E. Quantitative export of FGF-2 occurs through an alternative, energy-dependent, non-ER/Golgi pathway. J Cell Physiol. 1995;162:388-399.
72. Moscatelli D. High and low affinity binding sites for basic fibroblast growth factor on cultured cells: absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells. J Cell Physiol. 1987;131:123-130.
73. Vlodavsky I, Folkman J, Sullivan R, Fridman R, Ishai Michaeli R, Sasse J, Klagsbrun M. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc Natl Acad Sci U S A. 1987;84:2292-2296.
74. Rogelj S, Klagsbrun M, Atzmon R, Kurokawa M, Haimovitz A, Fuks Z, Vlodavsky I. Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J Cell Biol. 1989;109:823-831.
75. Powell PP, Klagsbrun M. Three forms of rat basic fibroblast growth factor are made from a single mRNA and localize to the nucleus. J Cell Physiol. 1991;148:202-210.
76. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M. Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun. 1994;202:1705-1709.
77. Barnard JA, Graves-Deal R, Pittelkow MR, DuBois R, Cook P, Ramsey GW, Bishop PR, Damstrup L, Coffey RJ, Auto- and cross-induction within the mammalian epidermal growth factor-related peptide family. J Biol Chem. 1994;269:22817-22822.
78. Kevil C, Carter P, Hu B, DeBenedetti A. Translational enhancement of FGF-2 by eIF-4 factors, and alternate utilization of CUG and AUG codons for translation initiation. Oncogene. 1995;11:2339-2348.
79. Vagner S, Gensac M-C, Maret A, Bayard F, Amalric F, Prats H, Prats A-C. Alternative translation of human fibroblast growth factor 2 mRNA occurs by internal entry of ribosomes. Mol Cell Biol. 1995;15:35-44.